Strong Inhibition of Wild-Type and Integrase Inhibitor (INI)-Resistant HIV Integrase (IN) Strand Transfer Reaction by the Novel INI S/GSK1349572

Conference Reports for NATAP

International HIV and Hepatitis Drug Resistance Workshop
June 8-12, 2010,
Dubrovnik Croatia


Strong Inhibition of Wild-Type and Integrase Inhibitor (INI)-Resistant HIV Integrase (IN) Strand Transfer Reaction by the Novel INI S/GSK1349572

	Reported by Jules Levin International HIV & Hepatitis Virus Drug Resistance Workshop 8-12 June 2010, Dubrovnik, Croatia Tomokazu Yoshinaga, Mikiko Kanamori-Koyama, Takahiro Seki, Kayo Ishida, Erika Akihisa, Masanori Kobayashi, Akihiko Sato, Tamio FujiwaraShionogi, Osaka, Japan 1.Min S, et al. IAS 2009, Cape Town, abstract WEPEA099. 2.Song I, et al. IAS 2009, Cape Town, abstract WEPEB250. 3.Sato A, et al. IAS 2009, Cape Town, abstract WEPEA097. 4.Underwood M, et al. IAS 2009, Cape Town, abstract WEPEA098. 5.Seki T, et al. CROI 2010, Poster abstract 555. Johns B, et al. The Discovery of S/GSK1349572: A Once Daily Next Generation Integrase Inhibitor with a Superior Resistance Profile. 17th CROI, San Francisco. Oral Session #55. Seki, T, et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones. 17th CROI, San Francisco. Poster #555. Hightower K., et. al., IDRW 2010, Dubrovnik, Croatia. GSK1349572RaltegravirElvitegravirSeki T., et al. CROI 2010, San Francisco, CA, USA.